Abstract: Provided herein are methods for EEG monitoring of a patient, which includes: positioning an array comprising a plurality of EEG electrodes on the patient's head; recording, during a first time period, a first data set of EEG signals from a first set of spatial scalp locations; manipulating the array to record, during a second time period, a second data set of EEG signals from a second set of spatial locations including at least some spatial scalp locations that are different from the first set of spatial scalp locations; integrating the first and second data sets, thereby generating a combined data set with a higher spatial density; and processing the combined data set to determine EEG events.

Abstract: A method of producing cell derived particles is disclosed. The method comprising isolating cell-derived particles from a biological sample comprising cells modified to present CD24 so as to obtain a preparation of the cell-derived particles substantially devoid of intact cells. Cell derived particles, a culture medium and a cell culture are also disclosed.

Abstract: A method of generating a population of genetically modified veto cells is disclosed. The method comprising: (a) providing a population of cells comprising T cells, the T cells comprising at least 40% memory CD8+ T cells; (b) culturing the population of cells comprising T cells with an antigen or antigens under conditions which allow enrichment of tolerance-inducing antigen-specific cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being depleted of graft versus host (GVH) reactivity; and (c) transducing the cells with a polynucleotide encoding a heterologous cell surface receptor comprising a T cell receptor signaling module, thereby generating the population of genetically modified veto cells.

Abstract: Compounds represented by Formula A as defined in the specification for use in treating skin diseases such as, for example, psoriasis, or atopic dermatitis, in a subject in need thereof are disclosed. Compositions containing these compounds, formulated for topical application, are also disclosed.

Abstract: A method of prognosing a subject diagnosed with multiple myeloma (MM) is provided. Also provided a method of treating a subject diagnosed with MM selected expressing intracellular PPIA and/or RRM2 above a predetermined threshold, the method comprising administering to the subject a therapeutically effective amount of at least one agent which specifically down-regulates activity or expression of PPIA and/or RRM2, thereby treating the subject.

Abstract: A composition comprising cell-derived particles presenting heterologous CD24, wherein the cell is a non-cancerous cell and wherein the composition is substantially devoid of intact cells is disclosed. Methods of producing the cell-derived particles and methods of using the cell-derived particles in treatment of cytokine storm syndrome, tissue injury associated with the inflammation and Coronavirus infection are also disclosed.

Abstract: A neurofeedback method, including: recording electrical signals from at least one brain region of a subject, wherein changes in the recorded electrical signals over time indicate changes in an activity level of the at least one brain region; providing an audio signal having a perceived quality based on the recorded electrical signals and according to an activity level of the at least one brain region; delivering the audio signal to the subject during said recording.

Abstract: A method of treating atopic dermatitis (AD) in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of at least two species of bacteria.

Abstract: The invention relates to a novel highly selective and potent NPP1 inhibitors, compositions comprising such, and their use as pharmaceuticals.

Abstract: An anti-CD24 antibody is provided. Accordingly, there is provided an antibody comprising an antigen recognition domain which specifically binds CD24 and comprises complementarity determining regions (CDRs) as set forth in SEQ ID NOs: 2, 3 and 4 arranged in a sequential order from N to C on a light chain of the antibody and CDRs as set forth in SEQ ID NOs: 6, 7 and 8 arranged in a sequential order from N to C on a heavy chain of said antibody. Also provided are polynucleotides encoding the antibody, host cells expressing the antibody the uses thereof.

Abstract: A method of producing cell derived particles is disclosed. The method comprising isolating cell-derived particles from a biological sample comprising cells modified to present CD24 so as to obtain a preparation of the cell-derived particles substantially devoid of intact cells. Cell derived particles, a culture medium and a cell culture are also disclosed.

Abstract: A composition comprising cell-derived particles presenting heterologous CD24, wherein the cell is a non-cancerous cell and wherein the composition is substantially devoid of intact cells is disclosed. Methods of producing the cell-derived particles and methods of using the cell-derived particles in treatment of cytokine storm syndrome, tissue injury associated with the inflammation and Coronavirus infection are also disclosed.